|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01184 |
Gene summary for LINC01184 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01184 | Gene ID | 644873 |
| Gene name | long intergenic non-protein coding RNA 1184 | |
| Gene Alias | LINC01184 | |
| Cytomap | 5q23.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 644873 | LINC01184 | S028 | Human | Liver | HCC | 1.14e-08 | 6.03e-01 | 0.2503 |
| 644873 | LINC01184 | S029 | Human | Liver | HCC | 1.69e-13 | 7.90e-01 | 0.2581 |
| 644873 | LINC01184 | RNA-P17T-P17T-8 | Human | Lung | IAC | 3.95e-02 | 2.67e-01 | 0.3329 |
| 644873 | LINC01184 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 7.49e-05 | 4.12e-01 | -0.2116 |
| 644873 | LINC01184 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 3.55e-03 | 5.06e-01 | -0.2107 |
| 644873 | LINC01184 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.72e-08 | 6.02e-01 | -0.2119 |
| 644873 | LINC01184 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.74e-08 | 3.80e-01 | -0.0166 |
| 644873 | LINC01184 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 9.91e-10 | 3.57e-01 | -0.0132 |
| 644873 | LINC01184 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.30e-18 | 4.83e-01 | -0.013 |
| 644873 | LINC01184 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 3.20e-10 | 4.30e-01 | -0.0121 |
| 644873 | LINC01184 | C04 | Human | Oral cavity | OSCC | 7.30e-07 | 6.13e-01 | 0.2633 |
| 644873 | LINC01184 | C21 | Human | Oral cavity | OSCC | 5.08e-37 | 1.04e+00 | 0.2678 |
| 644873 | LINC01184 | C30 | Human | Oral cavity | OSCC | 3.47e-37 | 1.61e+00 | 0.3055 |
| 644873 | LINC01184 | C38 | Human | Oral cavity | OSCC | 2.91e-04 | 7.76e-01 | 0.172 |
| 644873 | LINC01184 | C43 | Human | Oral cavity | OSCC | 1.58e-10 | 3.13e-01 | 0.1704 |
| 644873 | LINC01184 | C46 | Human | Oral cavity | OSCC | 2.30e-10 | 3.27e-01 | 0.1673 |
| 644873 | LINC01184 | C51 | Human | Oral cavity | OSCC | 1.14e-05 | 4.91e-01 | 0.2674 |
| 644873 | LINC01184 | C07 | Human | Oral cavity | OSCC | 6.48e-03 | 6.01e-01 | 0.2491 |
| 644873 | LINC01184 | C08 | Human | Oral cavity | OSCC | 1.40e-26 | 6.54e-01 | 0.1919 |
| 644873 | LINC01184 | C09 | Human | Oral cavity | OSCC | 1.15e-02 | 2.71e-01 | 0.1431 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |